Stéphane Bancel & Moderna

Stéphane Bancel: As CEO, Bancel championed the vaccine and highlighted its importance for seniors and the company's future.

Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.

Stéphane Bancel: Stéphane Bancel, CEO of Moderna, pledged urgency and scientific rigor in developing a Bundibugyo vaccine.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Stéphane Bancel: Moderna's CEO called the results a pivotal moment and said the product could be approved as soon as 2027.

Moderna: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and adding about $40 billion in market value. The trial success validates its mRNA platform and could lead to a new revenue stream, helping the company return to profitability.

Stéphane Bancel: Stéphane Bancel>>>, CEO of Moderna>>>, expressed pride in the expanded collaboration, highlighting Moderna's>>> commitment to rapid response to infectious disease threats.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

Stéphane Bancel: CEO Stéphane Bancel expressed delight at McDonnell's appointment, citing his industry understanding.

Moderna: Moderna appointed Michael Francis Crotty to its board, gaining financial expertise as it prepares for product launches.

Stéphane Bancel: Stéphane Bancel, CEO of Moderna, expressed appreciation for the VRBPAC's review and highlighted the potential of mRNA-1010 to offer a new option for seasonal flu prevention, reinforcing the company's commitment to the vaccine.

Moderna: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.

Stéphane Bancel: Stéphane Bancel, CEO of Moderna, expressed appreciation for the United States — Food and Drug Administration's engagement and agreement to review the vaccine, highlighting the company's goal to make the flu vaccine available to seniors.

Stéphane Bancel: Stéphane Bancel, Moderna's CEO, expressed disappointment with the United States — Food and Drug Administration's decision, stating it does not further shared goals of innovation.